Intas Pharmaceuticals, Ltd. is a global independent generic pharmaceutical company headquartered in India. With strong R&D and manufacturing capabilities and many years of experience in highly regulated markets, Intas delivered sales of USD 1.4 bM in 2017/18.Intas is an important 3rd Party licensor and is proud to supply more than 100 different finished products to more than 80 pharmaceutical companies in EMEA, APAC, CANADA and LATAM. For its EU based customers, batch testing & release services are provided from its Barcelona lab. Intas currently operates 4 GMP sites in India, 2 in UK and 1 in Mexico, capable of doing tabs, caps, effervescent tabs, ointments for high potent drugs, onco orals and onco injectables, including pre-filled syringes.Intas is vertically integrated into APIs for some of its key products. Intas is also developing added value or difficult-to-make products in respiratory, women healthcare, dermatology, pain, CNS and CV with EU based CDMOs. Intas' biotech division runs an EMA GMP certified biopharmaceutical site in Ahmedabad for the production of recombinant proteins (cell culture or fermentation). Intas is proud to be the 1st Indian company to have registered and commercially marketed a biosimilar (“Accofil” brand for GCSF) and the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion in Europe for Pelgraz®, our version of pegylated Granulocyte-Colony Stimulating Factor (G-CSF). This will be the second in-house developed biosimilar launched in Europe.